BIO-Europe, the must-attend global biopharma partnering event, has a bold new vision for its 32nd annual conference to be held in Cologne, Germany, from 9-11 November 2026.
The vision moves BIO-Europe beyond Europe’s largest partnering event to become the neutral, credible forum where the full biopharma C-suite shapes not just partnerships, but the strategic direction of the industry worldwide.
As the biopharma industry navigates increasing complexity across regulation, clinical development, manufacturing, policy and financing, BIO-Europe is evolving to reflect the need for more connected, cross-functional decision-making.
Building on its unwavering commitment to open dialogue, constructive partnerships, and continued recognition of the international nature of the life science industry, BIO-Europe 2026 expands its programme to convene the full suite of C-level strategy executives.
Claire Macht, Senior Portfolio Director at Informa Connect, said: ‘BIO-Europe is the epicentre of biotech – in Europe, for the world. Today’s increasingly complex policy and operating environment demands cross-border collaboration and end-to-end thinking. Our renewed vision reflects this reality, as BIO-Europe evolves beyond Europe’s largest partnering event to become the neutral convening ground where senior decision-makers forge partnerships, shape strategy and set the agenda for the biopharma industry worldwide, across the full value chain.’
The renewed vision will be delivered through seven integrated tracks and high-impact plenary sessions, spanning regulatory, clinical and manufacturing strategy, alongside traditional dealmaking, therapeutic area and ecosystem streams.
The expanded programme is designed to provide strategy-focused content to fuel dialogue among decision-makers across the global life sciences ecosystem and the full biopharma value chain.
To register for the conference or pitch for a company presentation, find more information and registration options here.
